Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61

Cited In for PubMed (Select 9630120)

1.

Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada.

Djalalov S, Beca J, Amir E, Krahn M, Trudeau ME, Hoch JS.

Curr Oncol. 2015 Apr;22(2):84-96. doi: 10.3747/co.22.2120.

2.

Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.

You JH, Ming WK, Chan PK.

BMC Infect Dis. 2014 Nov 25;14:618. doi: 10.1186/s12879-014-0618-9.

3.

Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States.

Michaelidis CI, Zimmerman RK, Nowalk MP, Smith KJ.

BMC Public Health. 2014 Jul 15;14:718. doi: 10.1186/1471-2458-14-718.

4.

Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in Iran.

Khatibi M, Rasekh HR, Shahverdi Z, Jamshidi HR.

Iran J Pharm Res. 2014 Winter;13(Suppl):225-34.

5.

Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis.

Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN.

Clin Infect Dis. 2014 Jun;58(11):1507-14. doi: 10.1093/cid/ciu128. Epub 2014 Mar 31.

6.

Economic evaluation of access to musculoskeletal care: the case of waiting for total knee arthroplasty.

Mather RC 3rd, Hug KT, Orlando LA, Watters TS, Koenig L, Nunley RM, Bolognesi MP.

BMC Musculoskelet Disord. 2014 Jan 18;15:22. doi: 10.1186/1471-2474-15-22.

7.

Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults.

Michaelidis CI, Zimmerman RK, Nowalk MP, Fine MJ, Smith KJ.

J Gen Intern Med. 2014 Apr;29(4):579-86.

8.

Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults.

Smith KJ, Nowalk MP, Raymund M, Zimmerman RK.

Vaccine. 2013 Aug 20;31(37):3950-6. doi: 10.1016/j.vaccine.2013.06.037. Epub 2013 Jun 24.

9.

Is fidaxomicin worth the cost? An economic analysis.

Bartsch SM, Umscheid CA, Fishman N, Lee BY.

Clin Infect Dis. 2013 Aug;57(4):555-61. doi: 10.1093/cid/cit346. Epub 2013 May 23.

10.

Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia.

Smith KJ, Wateska A, Nowalk MP, Raymund M, Lee BY, Zimmerman RK, Fine MJ.

J Gen Intern Med. 2013 Sep;28(9):1157-64. doi: 10.1007/s11606-013-2400-x.

11.
12.

The potential economic value of screening hospital admissions for Clostridium difficile.

Bartsch SM, Curry SR, Harrison LH, Lee BY.

Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3163-71. doi: 10.1007/s10096-012-1681-z. Epub 2012 Jun 30.

13.

A cost-effectiveness analysis of "test" versus "treat" patients hospitalized with suspected influenza in Hong Kong.

You JH, Chan ES, Leung MY, Ip M, Lee NL.

PLoS One. 2012;7(3):e33123. doi: 10.1371/journal.pone.0033123. Epub 2012 Mar 29.

14.

The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients.

Song Y, Tai JH, Bartsch SM, Zimmerman RK, Muder RR, Lee BY.

Vaccine. 2012 May 21;30(24):3675-82. doi: 10.1016/j.vaccine.2012.03.031. Epub 2012 Mar 29.

15.

Optimal approach to improving trauma triage decisions: a cost-effectiveness analysis.

Mohan D, Barnato AE, Rosengart MR, Angus DC, Smith KJ.

Am J Manag Care. 2012 Mar 1;18(3):e91-e100.

16.

Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.

Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK.

JAMA. 2012 Feb 22;307(8):804-12. doi: 10.1001/jama.2012.169.

17.

Symptom Burden, Medication Detriment, and Support for the Use of the 15D Health-Related Quality of Life Instrument in a Chronic Pain Clinic Population.

Dick BD, Rashiq S, Verrier MJ, Ohinmaa A, Zhang J.

Pain Res Treat. 2011;2011:809071. doi: 10.1155/2011/809071. Epub 2011 Apr 17.

18.

Quality-adjusted life years lost to road crash injury: updating the injury impairment index.

Spicer RS, Miller TR, Hendrie D, Blincoe LJ.

Ann Adv Automot Med. 2011;55:365-77.

19.

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.

Jit M, Chapman R, Hughes O, Choi YH.

BMJ. 2011 Sep 27;343:d5775. doi: 10.1136/bmj.d5775.

20.

The potential economic value of a 'universal' (multi-year) influenza vaccine.

Lee BY, Tai JH, McGlone SM, Bailey RR, Wateska AR, Zimmer SM, Zimmerman RK, Wagner MM.

Influenza Other Respir Viruses. 2012 May;6(3):167-75. doi: 10.1111/j.1750-2659.2011.00288.x. Epub 2011 Sep 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk